GLUCOCORTICOID PHARMACOKINETICS - 08/09/11
Résumé |
Glucocorticoids (GC), administered topically or systemically, form the cornerstone of asthma therapy. Delivered systemically, GCs serve as a major component of rescue therapy for acute asthma exacerbations. They also serve as chronic supplemental therapy in patients with severe persistent asthma who remain symptomatic despite high-dose inhaled GC therapy. Inhaled GCs are now the preferred controller medication for all asthmatics except for those with the mildest disease.
Glucocorticoids have been used in the treatment of asthma for nearly 50 years, beginning soon after cortisone was first synthesized and following reports that cortisone and corticotropin were effective in the treatment of rheumatoid arthritis.34 The early studies with cortisone showed improvements in asthma symptoms and pulmonary function and reductions in the numbers of circulating lymphocytes and eosinophils.11, 27, 57 Since then, great strides have been made in the understanding of how GCs act at the molecular and cellular level and also in the awareness of the multitude of adverse effects associated with prolonged use of GCs. Inhaled GC preparations have been developed that, because of their high topical-to-systemic effects, have proven to be safe and very effective in the treatment of asthma. This article provides a broad overview of the structure, pharmacokinetics, and pharmacodynamics of both systemically administered and inhaled GCs.
Le texte complet de cet article est disponible en PDF.Plan
| Address reprint requests to Joseph D. Spahn, MD, National Jewish Medical and Research Center, 1400 Jackson Street (J-210), Denver, CO 80206 |
Vol 19 - N° 4
P. 709-723 - novembre 1999 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
